TF and peripheral arterial disease: Interestingly, blocking platelet CD36 with the monoclonal anti-CD36 antibody FA6.152 resulted in a further significant decrease of the thrombin peak in PRP triggered by low concentration of TF from the same patients with PAD for all three treatment regimes, whereas the lag time was not affected (Table 2).